4.6 Article

Cognitive decline in patients with prostate cancer: study protocol of a prospective cohort, NEON-PC

Journal

BMJ OPEN
Volume 11, Issue 2, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2020-043844

Keywords

neurological oncology; epidemiology; urological tumours; delirium & cognitive disorders

Funding

  1. FEDER through the Operational Programme Competitiveness and Internationalisation
  2. Foundation for Science and Technology-FCT (Portuguese Ministry of Science, Technology and Higher Education) [POCI-01-0145-FEDER-032358, PTDC/SAU-EPI/32358/2017]
  3. Unidade de Investigacao em Epidemiologia - Instituto de Saude Publica da Universidade do Porto (EPIUnit) - national funds from FCT [UIDB/04750/2020]
  4. project 'NEON-PC - Neuro-oncological complications of prostate cancer: longitudinal study of cognitive decline' [POCI-01-0145-FEDER-032358, PTDC/SAU-EPI/32358/2017]
  5. FCT [SFRH/BD/102181/2014, SFRH/BD/119390/2016]
  6. 'Programa Operacional Capital Humano' (POCH/FSE) [SFRH/BD/102181/2014, SFRH/BD/119390/2016]
  7. Fundação para a Ciência e a Tecnologia [SFRH/BD/119390/2016, PTDC/SAU-EPI/32358/2017, SFRH/BD/102181/2014] Funding Source: FCT

Ask authors/readers for more resources

This study aims to evaluate cognitive performance trajectories in prostate cancer patients and quantify the impact of the disease and treatments on cognitive decline. Participants will be recruited from two hospitals in Northern Portugal and undergo various assessments, with recruitment expected to continue until the first semester of 2021.
Introduction Prostate cancer is the most prevalent oncological disease among men in industrialised countries. Despite the high survival rates, treatments are often associated with adverse effects, including metabolic and cardiovascular complications, sexual dysfunction and, to a lesser extent, cognitive decline. This study was primarily designed to evaluate the trajectories of cognitive performance in patients with prostate cancer, and to quantify the impact of the disease and its treatments on the occurrence of cognitive decline. Methods Participants will be recruited from two main hospitals providing care to approximately half of the patients with prostate cancer in Northern Portugal (Portuguese Institute of Oncology of Porto and Sao Joao Hospital Centre), and will comprise a cohort of recently diagnosed patients with prostate cancer proposed for different treatment plans, including: (1) radical prostatectomy; (2) brachytherapy and/or radiotherapy; (3) radiotherapy in combination with androgen deprivation therapy and (4) androgen deprivation therapy (with or without chemotherapy). Recruitment began in February 2018 and is expected to continue until the first semester of 2021. Follow-up evaluations will be conducted at 1, 3, 5, 7 and 10 years. Sociodemographic, behavioural and clinical characteristics, anxiety and depression, health literacy, health status, quality of life, and sleep quality will be assessed. Blood pressure and anthropometrics will be measured, and a fasting blood sample will be collected. Participants' cognitive performance will be evaluated before treatments and throughout follow-up (Montreal Cognitive Assessment and Cube Test as well as Brain on Track for remote monitoring). All participants suspected of cognitive impairment will undergo neuropsychological tests and clinical observation by a neurologist. Ethics and dissemination The study was approved by the Ethics Committee of the hospitals involved. All participants will provide written informed consent, and study procedures will be developed to ensure data protection and confidentiality. Results will be disseminated through publication in peer-reviewed journals and presentation in scientific meetings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available